Literature DB >> 8387359

Synthesis and characterization of the hydrophilic C-terminal domain of the human immunodeficiency virus type 1-encoded virus protein U (Vpu).

P Henklein1, U Schubert, O Kunert, S Klabunde, V Wray, K D Klöppel, M Kiess, T Portsmann, D Schomburg.   

Abstract

The HIV-1-specific virus protein U (Vpu) is an amphipathic membrane-associated phosphoprotein that probably possesses an N-terminal hydrophobic membrane anchor and a hydrophilic moiety. Because of an as yet undefined cytotoxic effect and the low concentration of Vpu in host cells, it has not been possible to obtain sufficient quantities of this protein for biochemical and structural investigations. We describe the synthesis, in two forms, of 50-residue peptides representing the polar cytoplasmic domain of Vpu: pVpu, comprising the wild-type Vpu sequence of HIV-1, strain HTLVIIIB, from position Ile32 to Leu81, and a mutant, pVpum2/6, with replacement of Ser52-56 with Asn. This mutation affects the two phosphorylation sites of Vpu for casein kinase-2 (CK-2), the enzyme that phosphorylates Vpu in HIV-1-infected cells. The peptides were purified to homogeneity and characterized by N-terminal sequencing, mass spectrometry and SDS-PAGE. Furthermore, both peptides were immunologically characterized by Western blot and ELISA using Vpu-specific monoclonal and polyclonal antibodies. Recombinant human CK-2 caused in vitro phosphorylation of pVpu, but had no effect on the mutant pVpum2/6. Investigation of the peptides by circular dichroism showed that addition of trifluoroethanol stabilized the alpha-helical secondary structure. Preliminary 1H NMR spectroscopic data indicated that, in the presence of trifluoroethanol, both peptides in solution have stable secondary structures with considerable alpha-helical content.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8387359

Source DB:  PubMed          Journal:  Pept Res        ISSN: 1040-5704


  9 in total

1.  Casein kinase II is a selective target of HIV-1 transcriptional inhibitors.

Authors:  J W Critchfield; J E Coligan; T M Folks; S T Butera
Journal:  Proc Natl Acad Sci U S A       Date:  1997-06-10       Impact factor: 11.205

2.  The human immunodeficiency virus type 1 Vpu protein specifically binds to the cytoplasmic domain of CD4: implications for the mechanism of degradation.

Authors:  S Bour; U Schubert; K Strebel
Journal:  J Virol       Date:  1995-03       Impact factor: 5.103

3.  Putative alpha-helical structures in the human immunodeficiency virus type 1 Vpu protein and CD4 are involved in binding and degradation of the CD4 molecule.

Authors:  E Tiganos; X J Yao; J Friborg; N Daniel; E A Cohen
Journal:  J Virol       Date:  1997-06       Impact factor: 5.103

Review 4.  Relating structure and function of viral membrane-spanning miniproteins.

Authors:  Stanley J Opella
Journal:  Curr Opin Virol       Date:  2015-06-06       Impact factor: 7.090

Review 5.  HIV-1 Vpu targets cell surface markers CD4 and BST-2 through distinct mechanisms.

Authors:  Amy Andrew; Klaus Strebel
Journal:  Mol Aspects Med       Date:  2010-09-19

Review 6.  The human immunodeficiency virus type 1 (HIV-1) CD4 receptor and its central role in promotion of HIV-1 infection.

Authors:  S Bour; R Geleziunas; M A Wainberg
Journal:  Microbiol Rev       Date:  1995-03

7.  Differential activities of the human immunodeficiency virus type 1-encoded Vpu protein are regulated by phosphorylation and occur in different cellular compartments.

Authors:  U Schubert; K Strebel
Journal:  J Virol       Date:  1994-04       Impact factor: 5.103

Review 8.  Modulation of HIV-1-host interaction: role of the Vpu accessory protein.

Authors:  Mathieu Dubé; Mariana G Bego; Catherine Paquay; Éric A Cohen
Journal:  Retrovirology       Date:  2010-12-22       Impact factor: 4.602

9.  Predicting CK2 beta-dependent substrates using linear patterns.

Authors:  Teresa Núñez de Villavicencio-Díaz; Yuliet Mazola; Yasser Perera Negrín; Yiliam Cruz García; Osmany Guirola Cruz; Silvio E Perea Rodríguez
Journal:  Biochem Biophys Rep       Date:  2015-08-20
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.